Pervin Tahmina, Oany Arafat Rahman
Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Khulna, 9208 Bangladesh.
Department of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, 1902 Bangladesh.
In Silico Pharmacol. 2021 Mar 6;9(1):21. doi: 10.1007/s40203-021-00080-3. eCollection 2021.
Marburg virus is one of the world's most threatening diseases, causing extreme hemorrhagic fever, with a death rate of up to 90%. The Food and Drug Administration (FDA) currently not authorized any treatments or vaccinations for the hindrance and post-exposure of the Marburg virus. In the present study, the vaccinomics methodology was adopted to design a potential novel peptide vaccine against the Marburg virus, targeting RNA-directed RNA polymerase (l). A total of 48 l-proteins from diverse variants of the Marburg virus were collected from the NCBI GenBank server and used to classify the best antigenic protein leading to predict equally T and B-cell epitopes. Initially, the top 26 epitopes were evaluated for the attraction with major histocompatibility complex (MHC) class I and II alleles. Finally, four prospective central epitopes NLSDLTFLI, FRYEFTRHF, YRLRNSTAL, and YRVRNVQTL were carefully chosen. Among these, FRYEFTRHF and YRVRNVQTL peptides showed 100% conservancy. Though YRLRNSTAL showed 95.74% conservancy, it demonstrated the highest combined score as T cell epitope (2.5461) and population coverage of 94.42% among the whole world population. The epitope was found non-allergenic, and docking interactions with human leukocyte antigens (HLAs) also verified. Finally, in vivo analysis of the recommended peptides might contribute to the advancement of an efficient and exclusively prevalent vaccine that would be an active route to impede the virus spreading.
The online version contains supplementary material available at 10.1007/s40203-021-00080-3.
马尔堡病毒是世界上最具威胁的疾病之一，可引发严重出血热，死亡率高达90%。美国食品药品监督管理局（FDA）目前未批准任何针对马尔堡病毒的预防和暴露后治疗方法或疫苗。在本研究中，采用疫苗组学方法设计了一种针对马尔堡病毒的潜在新型肽疫苗，靶向RNA依赖性RNA聚合酶（l）。从NCBI基因库服务器收集了来自马尔堡病毒不同变体的48种l蛋白，并用于分类最佳抗原蛋白，以预测同等的T细胞和B细胞表位。最初，对排名前26的表位与主要组织相容性复合体（MHC）I类和II类等位基因的亲和力进行了评估。最后，精心挑选了四个潜在的中心表位NLSDLTFLI、FRYEFTRHF、YRLRNSTAL和YRVRNVQTL。其中，FRYEFTRHF和YRVRNVQTL肽显示100%保守性。虽然YRLRNSTAL显示95.74%的保守性，但它作为T细胞表位的综合得分最高（2.5461），在全球人群中的群体覆盖率为94.42%。该表位被发现无致敏性，与人类白细胞抗原（HLA）的对接相互作用也得到了验证。最后，对推荐肽的体内分析可能有助于推进一种高效且普遍适用的疫苗，这将是阻止病毒传播的有效途径。
在线版本包含可在10.1007/s40203-021-00080-3获取的补充材料。
